BlendsMetabolic

Cagrilintide 5mg + Semaglutide 5mg

Dual peptide blend · Amylin + GLP-1 analogues · Synthetic

FDA · PHASE 3 TRIALS (CAGRISEMA)

Half-life

~7 days

Very long

minsdays

Route

SubQ injection

Evidence

Clinical trial data

Risk

Standard

Overview

Known for

CagriSema combination. Dual-mechanism weight loss targeting both GLP-1 and amylin pathways simultaneously. Clinical trials showed ~25% weight loss. Potentially the most effective approved-pathway combination.

Mechanism

Dual pathway: amylin + GLP-1. Targets two separate satiety mechanisms for additive weight loss effect.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Active
Supply & nature
ExogenousExogenous
FDA category
Phase 3 trials (CagriSema)

Evidence & standing

Evidence base
Clinical trial data
Risk level
Standard
Clinical phase
Phase 3
Best studies
4 references
  • Frias et al. (2023) CagriSema Phase 2 in T2D. NEJM 389:1151-62. DOI: 10.1056/NEJMoa2306584
  • REDEFINE Phase 3 program ongoing (Novo Nordisk)
  • NOT YET FDA APPROVED
  • ClinicalTrials.gov: NCT05567796

Dosage & protocol

Typical dose
Must titrate both
Cycle
Weekly injection
Onset
10 days first effects
Full effect
168 days
Half-life
~7d each
Components: Cagri ~7d + Sema ~7d
Protocol

Must titrate both components. Follow individual titration schedules. Consult specific CagriSema protocols.

Time to effects

EARLY: 1-2 weeks

FULL: 16-32 weeks

Dual mechanism means effects may be felt slightly faster than either compound alone.

Week 1-2: Appetite suppression from both pathways.

Week 4-8: Visible weight loss.

Week 16-32: ~25% body weight loss in trials at 32 weeks.

Minimum commitment: 16 weeks for meaningful assessment.

Recommended vial
  • 5mg+5mg (only size)

Duration depends on dose titration. Monitor shelf life carefully during low-dose phases.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Unknown
Side effects

Combined side effect profile of both: nausea (up to 45%), GI effects more pronounced than either alone

Interactions

All GLP-1 interactions + amylin/insulin interactions

Do not combine
CagrilintideCagrilintide RetatrutideRetatrutide SemaglutideSemaglutide SurvodutideSurvodutide TirzepatideTirzepatide

Handle with research caution

  • Do NOT combine with any other GLP-1 agonist (Tirzepatide, Retatrutide, standalone Semaglutide)
  • Already a dual-mechanism compound — adding more = toxicity not efficacy

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
4–6 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.